Criteria

What We Look For

We are interested in healthcare businesses and venture ideas where clinical knowledge, experienced leadership, technology, disciplined execution, and the right relationships can create meaningful value.

We especially value opportunities led or strongly informed by physicians, nurses, clinicians, caregivers, and other professionals with direct care-delivery experience.

Our Investment Focus

We invest in healthcare delivery innovations that address the most pressing needs in post-hospital and community-based care settings.

Home-Based and Transitional Care

Solutions that deliver hospital-quality care in patients' homes and smooth transitions between care settings.

Key Areas:

  • Post-acute care management
  • Remote patient monitoring
  • Medication management
  • Care coordination

AI-Enhanced Diagnostic and Care Navigation

Machine learning tools that augment clinical decision-making and guide patients through complex healthcare systems.

Key Areas:

  • Clinical decision support
  • Predictive analytics
  • Care pathway optimization
  • Risk stratification

Community-Based Chronic Care Management

Longitudinal care models that meet patients where they are and prevent costly exacerbations.

Key Areas:

  • Diabetes management
  • Heart failure care
  • Mental health support
  • Preventive care

New Reimbursement and Risk-Bearing Models

Innovative payment structures that align incentives with patient outcomes rather than volume.

Key Areas:

  • Value-based care
  • Bundled payments
  • Capitation models
  • Shared savings programs

Examples

Six opportunities your sales team could be pitching this quarter.

Each one is something CMS or a payer is already paying to solve. The Opportunity Atlas shows you which markets, which buyers, and how to frame the ask.

Use these as templates. The Opportunity Atlas produces a custom set for your product, segment, and geography.

01 · OPPORTUNITY

Sleep Apnea: Therapy Fulfillment Gap

  • HCPCS 95810
  • HCPCS E0601
  • MA Stars

THE SIGNAL

Markets where diagnostic sleep test volume (HCPCS 95810) is high, but therapy fulfillment (CPAP HCPCS E0601) lags by 30%+.

WHY CMS / PAYERS PAY FOR THIS

MA plans lose triple-weighted Star points on care coordination when diagnosed patients are never started on therapy.

SALES NARRATIVE

“Stop losing patients at diagnosis. We have identified the 12 counties where your DME network is missing 40% of the therapy volume you have already paid to diagnose.”

WHO BUYS

DME Suppliers · Sleep Clinic MSOs · MA Plan Operations

02 · OPPORTUNITY

COPD: Hospital-to-Home Shift

  • DRG 190-192
  • HCPCS E1392
  • Readmit Penalities

THE SIGNAL

States with top-quartile Inpatient spend but bottom-decile Home Oxygen utilization (HCPCS E1392).

WHY CMS / PAYERS PAY FOR THIS

CMS penalizes 30-day COPD readmissions. Home oxygen and pulmonary rehab prevent ER visits at a fraction of admission cost.

SALES NARRATIVE

“Recover your MA Star points and cut avoidable admissions — funded by home oxygen workflows you are already eligible to bill.”

WHO BUYS

Health System VPs of Value-Based Care · ACO Quality Officers

03 · OPPORTUNITY

Heart Failure: RPM Revenue Transition

  • CPT 99457
  • CPT 99458
  • BPCI-A

THE SIGNAL

High economic density (spend per patient) but near-zero utilization of Remote Physiological Monitoring (RPM) codes.

WHY CMS / PAYERS PAY FOR THIS

Transitions of care are high-risk. RPM creates a continuous care bridge that protects BPCI-A bundle savings.

SALES NARRATIVE

“Turn your Heart Failure discharge program into a paid workflow. Less than 2% of eligible CHF beneficiaries in high-spend counties are enrolled in a digital bridge.”

WHO BUYS

Cardiology Groups · MSOs · Post-Acute Care Leaders

04 · OPPORTUNITY

Type 2 Diabetes: Silent Nephropathy Screen

  • CPT 83036
  • CPT 82465
  • HEDIS

THE SIGNAL

High volume of E&M visits (99213/99214) but low utilization of critical kidney screening labs.

WHY CMS / PAYERS PAY FOR THIS

Dialysis is the single largest cost driver for MA plans. Early detection of kidney disease in diabetic cohorts saves millions in long-term claims.

SALES NARRATIVE

“Your diabetic population has a 40% screening gap in high-density regions. Close it now to save $12k per patient in avoided dialysis costs.”

WHO BUYS

MA Quality Leaders · Primary Care Network Managers

05 · OPPORTUNITY

Parkinson’s: Neurology Access Optimisation

  • Specialty ROI
  • Fall Prevention
  • SNF Avoidance

THE SIGNAL

Geographic hotspots where Parkinson’s prevalence is high, but the primary specialty managing care is Internal Medicine rather than Neurology.

WHY CMS / PAYERS PAY FOR THIS

Specialist-led care reduces fall-related fractures and expensive Skilled Nursing Facility (SNF) stays.

SALES NARRATIVE

“Your Parkinson’s members are being managed by GPs without specialised protocols. We found where a Neurologist partnership yields the highest ROI.”

WHO BUYS

Neurological MSOs · Payer Network Strategy Leads

06 · OPPORTUNITY

Hypertriglyceridaemia: Metabolic Market Density

  • MLR Reduction
  • Specialty Pharma
  • Allowed/Patient

THE SIGNAL

States where allowed spend per patient is more than 2x the national average for metabolic conditions.

WHY CMS / PAYERS PAY FOR THIS

Managing high-cost metabolic tiers reduces long-term cardiovascular event spend, a primary driver of Medical Loss Ratios (MLR).

SALES NARRATIVE

“Optimise your metabolic sales force. Here are the 10 states where spend-per-patient indicates a premium specialty clinical service opportunity.”

WHO BUYS

Specialty Pharma BD · Metabolic Centre Developers

How we evaluate

The questions we ask

  1. 01Does the company address a real problem affecting patients, caregivers, clinicians, or care teams?
  2. 02Can it improve the end-to-end care experience rather than optimizing only one isolated transaction?
  3. 03Can it produce better clinical, functional, financial, safety, access, or quality-of-life outcomes?
  4. 04Can it reduce unnecessary work or cognitive burden for clinicians?
  5. 05Does it make appropriate care easier to deliver or receive?
  6. 06Can its impact be measured using credible and practical indicators?
  7. 07Is the business model aligned with better care rather than dependent on avoidable waste or friction?
  8. 08Can VIPCare Health's capital, operating support, technology, and relationships materially improve its chances of success?

We do not require every opportunity to address every question. Each portfolio company should have a credible connection to improved care delivery and meaningful patient, caregiver, or clinician impact.

Partnership paths

Where you might fit

For Clinician Founders

Turn firsthand knowledge of a healthcare problem into a well-structured and properly supported business.

Start here

For Business Owners

Explore a sale, recapitalization, growth investment, or long-term operating partnership.

Start here

For Entrepreneurs

Develop a healthcare idea through the VIPCare Health venture-studio model.

Start here

For Investors and Funding Partners

Participate at the holding-company, fund, acquisition, or portfolio-company level.

Start here

For Healthcare Executives

Lead, advise, or operate a growing portfolio company. We give preference to executives with meaningful clinical care-delivery experience or a demonstrated ability to work closely with clinical leaders.

Start here

For Strategic Partners

Bring an opportunity, relationship, capability, or market need that could support a new or existing healthcare venture.

Start here